D. Echo

A phase I trial of the small molecule pan-bcl-2 inhibitor obatoclax (GX15–070) in combination with docetaxel in patients with relapsed non-small cell lung cancer (NSCLC)

C. Williams, M. Berger, M. Edelman, 2008 .

Predicting genitourinary toxicity in patients receiving cisplatin-based combination chemotherapy: a cancer and leukemia group B study

James R. Anderson, Mark R. Green, K. Propert, 2004, Cancer Chemotherapy and Pharmacology.

Preliminary results of outpatient hepatic artery brachytherapy for colorectal hepatic metastases

R. Murthy, A. Kennedy, D. Echo, 2001 .

Clinical and pharmacologic study of tributyrin: an oral butyrate prodrug

M. Edelman, J. Karp, J. Trepel, 2003, Cancer Chemotherapy and Pharmacology.

Phase II study of docetaxel and topotecan combination chemotherapy in patients with advanced head and neck cancer

R. Haddad, D. Echo, 2003, Cancer Chemotherapy and Pharmacology.

Esorubicin (4′‐Deoxydoxorubicin, NSC 267469) in Advanced Breast Cancer: A Phase II Study of the CALGB

W. Wood, N. Vogelzang, I. Henderson, 1990, American journal of clinical oncology.

Plasma kinetics of aclacinomycin A and its major metabolites in man

M. Egorin, M. Whitacre, N. R. Bachur, 2004, Cancer Chemotherapy and Pharmacology.

The Clinical Pharmacology of Aclacinomycin-A

M. Egorin, H. Nakazawa, N. Bachur, 1982 .